Untying the Gordian Knot: Exploring Novel Treatments and Future Prospects in TNBC ~ Patient Case Simulation
Activity Post-Survey & Application for Credit

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 75% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

1. What are your specialty & credentials? (Required.)

MD/DO - Medical Oncologist

MD/DO - Surgical Oncologist

MD/DO - Radiologist

MD/DO - Pathologist

Trainee/Fellow

Nurse

Pharmacist

Other (please specify)

Question Title

2. What is your community of practice?

Academic

Community

Industry

Other (please specify)

Question Title

3. What contributes to increased mortality risk among African American/Black patients vs White patients w/ TNBC? (Required.)

Increased frequency of BRCA1 mutations

Dx & treatment delays

Overtreatment

Question Title

4. Which of the following are the correct target and payload of sacituzumab govitecan? (Required.)

TROP2 & SN-38

HER2 & top I inhibitor

Nectin-4 & MMAE

FRα & DM4

Question Title

5. How often should patients receiving T-DXd be monitored for development of ILD with a chest CT 🫁? (Required.)

Every 6-12 weeks

Every 4-6 months

Every 7-9 months

Annually

Question Title

6. Your 50-old patient with mTNBC has stable disease after completing 4 cycles of sacituzumab govitecan. How should you manage her? (Required.)

Continue sacituzumab govitecan

Stop sacituzumab govitecan

Switch to fam-trastuzumab deruxtecan-nxki

Start maintenance capecitabine

Question Title

7. You have a 58-year-old patient who is starting on sacituzumab govitecan after her mTNBC progressed on doxorubicin. Her baseline labs are within normal limits. Which grade 3 adverse events is she most likely to develop? (Required.)

Anemia and peripheral neuropathy

Thrombocytopenia and pneumonitis

Neutropenia and diarrhea

Leukopenia and constipation

EVALUATION FORM

Question Title

8. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
IDENTIFY guideline-directed evidence-based approaches for molecular testing for patients diagnosed with TNBC	IDENTIFY guideline-directed evidence-based approaches for molecular testing for patients diagnosed with TNBC Strongly agree	IDENTIFY guideline-directed evidence-based approaches for molecular testing for patients diagnosed with TNBC Agree	IDENTIFY guideline-directed evidence-based approaches for molecular testing for patients diagnosed with TNBC Disagree	IDENTIFY guideline-directed evidence-based approaches for molecular testing for patients diagnosed with TNBC Strongly disagree
SUMMARIZE the clinical safety and efficacy data, AE profiles, and AE management approaches for recently approved and emerging targeted therapies for patients with mTNBC.	SUMMARIZE the clinical safety and efficacy data, AE profiles, and AE management approaches for recently approved and emerging targeted therapies for patients with mTNBC. Strongly agree	SUMMARIZE the clinical safety and efficacy data, AE profiles, and AE management approaches for recently approved and emerging targeted therapies for patients with mTNBC. Agree	SUMMARIZE the clinical safety and efficacy data, AE profiles, and AE management approaches for recently approved and emerging targeted therapies for patients with mTNBC. Disagree	SUMMARIZE the clinical safety and efficacy data, AE profiles, and AE management approaches for recently approved and emerging targeted therapies for patients with mTNBC. Strongly disagree

Question Title

9. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Disagree	Strongly disagree
The faculty for this activity were effective	The faculty for this activity were effective Strongly agree	The faculty for this activity were effective Agree	The faculty for this activity were effective Disagree	The faculty for this activity were effective Strongly disagree
The educational resources provided to me at the educational activity are useful to my practice	The educational resources provided to me at the educational activity are useful to my practice Strongly agree	The educational resources provided to me at the educational activity are useful to my practice Agree	The educational resources provided to me at the educational activity are useful to my practice Disagree	The educational resources provided to me at the educational activity are useful to my practice Strongly disagree

Question Title

10. Overall, was this activity fair, balanced and free from commercial bias?

Yes

Question Title

11. If no, please explain:

Question Title

12. Of the patients with TNBC you will see in the next month, about how many will benefit from the information you learned today?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

Question Title

13. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Expanded use of novel therapies and appropriate uses in TNBC

Application of cutting-edge science in this therapeutic area

Appropriate sequencing of therapeutics

Monitoring and mitigation of TRAEs

Implementation of best practices of my colleagues and leaders

I do not plan on making changes to my practice at this time

Other (explain)

Question Title

14. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding treatment options (patient-related)

Patient adherence/resistance to new therapeutics and/or clinical trial enrollment (patient-related barrier)

Limited knowledge regarding new therapeutics for TNBC (provider-level barrier)

Lack of time resources to consider change (practice-related barrier)

Inadequate support staff for pt education/insurance/billing/administrative issues (practice-level barrier)

Insurance reimbursement or legal issues (systems-related barrier)

Lack of access to novel therapeutics due to regulatory approvals/insurance coverage (systems-related barrier)

Other (please specify)

Question Title

15. For purposes of certification, you must complete the following information.
Please note that we will not forward or sell your contact information. (Required.)

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Question Title

16. I certify that I have participated in the continuing education activity entitled, "Untying the Gordian Knot: Exploring Novel Treatments and Future Prospects in TNBC ~ Patient Case Simulation" and claim 1.0 AMA PRA Category 1 Credit^TM. (Required.)

Yes

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Untying the Gordian Knot: Exploring Novel Treatments and Future Prospects in TNBC ~ Patient Case Simulation*Activity Post-Survey & Application for Credit*

Question Title

* 1. What are your specialty & credentials? (Required.)

Question Title

* 2. What is your community of practice?

Question Title

* 3. What contributes to increased mortality risk among African American/Black patients vs White patients w/ TNBC? (Required.)

Question Title

* 4. Which of the following are the correct target and payload of sacituzumab govitecan? (Required.)

Question Title

* 5. How often should patients receiving T-DXd be monitored for development of ILD with a chest CT 🫁? (Required.)

Question Title

* 6. Your 50-old patient with mTNBC has stable disease after completing 4 cycles of sacituzumab govitecan. How should you manage her? (Required.)

Question Title

* 7. You have a 58-year-old patient who is starting on sacituzumab govitecan after her mTNBC progressed on doxorubicin. Her baseline labs are within normal limits. Which grade 3 adverse events is she most likely to develop? (Required.)

Question Title

* 8. Upon completion of this activity, I am able to:

Question Title

* 9. Please indicate the extent of your agreement with the following statements:

Question Title

* 10. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 11. If no, please explain:

Question Title

* 12. Of the patients with TNBC you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 13. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 14. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 15. For purposes of certification, you must complete the following information. *Please note that we will not forward or sell your contact information.* (Required.)

Question Title

* 16. I certify that I have participated in the continuing education activity entitled, "Untying the Gordian Knot: Exploring Novel Treatments and Future Prospects in TNBC ~ Patient Case Simulation" and claim 1.0 AMA PRA Category 1 CreditTM. (Required.)

Untying the Gordian Knot: Exploring Novel Treatments and Future Prospects in TNBC ~ Patient Case Simulation
Activity Post-Survey & Application for Credit

1. What are your specialty & credentials? (Required.)

2. What is your community of practice?

3. What contributes to increased mortality risk among African American/Black patients vs White patients w/ TNBC? (Required.)

4. Which of the following are the correct target and payload of sacituzumab govitecan? (Required.)

5. How often should patients receiving T-DXd be monitored for development of ILD with a chest CT 🫁? (Required.)

6. Your 50-old patient with mTNBC has stable disease after completing 4 cycles of sacituzumab govitecan. How should you manage her? (Required.)

7. You have a 58-year-old patient who is starting on sacituzumab govitecan after her mTNBC progressed on doxorubicin. Her baseline labs are within normal limits. Which grade 3 adverse events is she most likely to develop? (Required.)

8. Upon completion of this activity, I am able to:

9. Please indicate the extent of your agreement with the following statements:

10. Overall, was this activity fair, balanced and free from commercial bias?

11. If no, please explain:

12. Of the patients with TNBC you will see in the next month, about how many will benefit from the information you learned today?

13. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

14. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

15. For purposes of certification, you must complete the following information.
Please note that we will not forward or sell your contact information. (Required.)

16. I certify that I have participated in the continuing education activity entitled, "Untying the Gordian Knot: Exploring Novel Treatments and Future Prospects in TNBC ~ Patient Case Simulation" and claim 1.0 AMA PRA Category 1 Credit^TM. (Required.)